NuvOx Pharma

The company's lead product candidate, NanO2™, is an injectable drug composed of dodecafluoropentane nanobubbles that captures oxygen in the lungs and transports it to oxygen-deprived tissues. This platform technology is designed to be synergistic with existing standards of care, enhancing their effectiveness. The business model centers on advancing NanO2™ through clinical trials to gain regulatory approval for various indications. The primary customers are comprehensive care centers for oncology, stroke, and respiratory illnesses, with a long-term strategy of partnering with large pharmaceutical companies for global commercialization.

NanO2™ has demonstrated a therapeutic effect in over 30 animal studies and has shown positive safety and efficacy data in completed Phase Ib/IIa human trials for glioblastoma (a type of brain cancer) and acute ischemic stroke. As a radiosensitizer, it aims to make cancer cells more susceptible to radiation and chemotherapy by increasing tumor oxygen levels. For stroke patients, it acts as a neuroprotectant, preserving brain tissue until blood flow can be restored. The company is advancing its clinical programs, with a Phase IIb trial underway for glioblastoma in the U.S. and another Phase IIb trial for stroke planned to begin in the U.K. in 2025. NuvOx has received significant non-dilutive funding from organizations like the National Institutes of Health (NIH) and BARDA, and has also raised capital from various angel investor groups.